Full text
Earnings transcript
Read the complete earnings call transcript.
IQV
IQVIA Holdings Inc.
$266.9
-4.14
(-1.53%)
| Exchange: | NYSE |
| Market Cap: | 43.932B |
| Shares Outstanding: | 125.468M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – Diagnostics & ResearchView industry performance | |||||
| CEO: | Ari Bousbib | |||||
| Full Time Employees: | 94000 | |||||
| Address: |
| |||||
| Website: | https://www.iqvia.com |
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company’s operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA’s diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Click to read more…
Revenue Segmentation
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| IQV | IQVIA Holdings Inc. | 43.9B | 32.0 | 20.6 | 8.3% |
 IDXX | IDEXX Laboratories, Inc. | 44.1B | 36.4 | 38.0 | 40.9% |
 WAT | Waters Corporation | 42.9B | 108 | 30.0 | 1.3% |
 ILMN | Illumina, Inc. | 39.6B | 51.4 | 49.0 | 13.5% |
 A | Agilent Technologies, Inc. | 48.8B | 33.5 | 27.9 | 11.9% |
 MTD | Mettler-Toledo International Inc. | 32.5B | 34.8 | 34.3 | 38.2% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 14,984,000 | 15,405,000 | 16,310,000 |
| Gross Profit | 5,239,000 | 5,375,000 | 5,430,000 |
| EBITDA | 3,256,000 | 3,453,000 | 2,938,000 |
| Operating Income | 1,977,000 | 2,202,000 | 2,182,000 |
| Net Income | 1,358,000 | 1,373,000 | 1,360,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 26,681,000 | 26,899,000 | 29,944,000 |
| Total Liabilities | 20,569,000 | 20,832,000 | 23,314,000 |
| Total Stockholders Equity | 6,112,000 | 6,067,000 | 6,503,000 |
| Total Debt | 13,896,000 | 14,156,000 | 16,174,000 |
| Cash and Cash Equivalents | 1,376,000 | 1,702,000 | 1,980,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 2,149,000 | 2,716,000 | 2,654,000 |
| Capital Expenditure | -649,000 | 0 | 0 |
| Free Cash Flow | 1,500,000 | 2,716,000 | 2,654,000 |
| Net Income | 1,358,000 | 1,373,000 | 1,361,000 |
| Net Change in Cash | 160,000 | 326,000 | 278,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 22,060,904.180 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 22,811,235.598 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 22,248,500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 5,643,572.543 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 5,828,259.856 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 5,689,748.448 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 3,546,362.575 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 3,703,567.456 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 3,585,667.265 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 2,971,556.507 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 3,072,624.540 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 2,996,825.262 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 20.670 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 21.350 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 20.440 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 7 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 5 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates IQV intrinsic value between $297.30 – $379.31 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about IQV valuation
Is IQVIA Holdings Inc. (IQV) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for IQVIA Holdings Inc. (IQV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is IQV a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IQV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is IQV’s P/E ratio?
You can see IQV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for IQV?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is IQV a good long-term investment?
Whether IQV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
IQV
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.53
Trading Metrics:
| Open: | 271.65 | Previous Close: | 271.04 | |
| Day Low: | 264.91 | Day High: | 272.88 | |
| Year Low: | 154.5 | Year High: | 277.4 | |
| Price Avg 50: | 259.33 | Price Avg 200: | 207.55 | |
| Volume: | 1.037M | Average Volume: | 1.467M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
